nach oben

Erschienen in:

01.04.2021 | Original Article

Genotypic and phenotypic features in Turkish patients with classic nonketotic hyperglycinemia

verfasst von: Harun Bayrak, Yılmaz Yıldız, Asburçe Olgaç, Çiğdem Seher Kasapkara, Aynur Küçükcongar, Ayşegül Zenciroğlu, Deniz Yüksel, Serdar Ceylaner, Mustafa Kılıç

Erschienen in: Metabolic Brain Disease | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Nonketotic hyperglycinemia is an autosomal recessive inborn error of glycine metabolism, characterized by deficient activity of the glycine cleavage enzyme system. Classic nonketotic hyperglycinemia is caused by mutations or genomic changes in genes that encode the protein components of the glycine cleavage enzyme system. We aimed to investigate clinical, biochemical, radiological findings and molecular genetic data in ten Turkish patients with classic nonketotic hyperglycinemia. Ten Turkish patients who were diagnosed with classic nonketotic hyperglycinemia in a single center from 2013 to 2019 were included in this study. Their clinical, radiological, electrophysiological and laboratory data were collected retrospectively. Sixty percent of the patients were in neonatal group, while 40 % of the patients were infantile. There were no late-onset patients. 90 % of the patients had the severe form. All patients had developmental delay and seizures. Mortality ratio was 30 % in all groups and 50 % in the neonatal group, while no mortality was seen in infantile group. Median (range) values of cerebrospinal fluid (CSF) glycine levels, plasma glycine levels and CSF/plasma glycine ratios were 148 (15–320) µmol/L, 896 (87-1910) µmol/L, 0.17 (0.09–0.21) respectively. Diffuse hypomyelination and corpus callosum anomaly were the most common cranial MRI findings and multifocal epileptic activity and burst supression pattern were the most common electroencephalographic findings. Six patients had variants in GLDC gene and four in AMT gene; five novel variants including AMT gene deletion were detected. Prognosis was poor and treatment was not effective, especially in the severe form. Classic nonketotic hyperglycinemia causes high morbidity and mortality. Neonatal-onset disease was more common and severe than infantile-onset disease. The ratio of AMT gene variants might be higher in Turkey than other countries. AMT gene deletion also plays a role in the etiology of classic nonketotic hyperglycinemia.

Aburahma S, Khassawneh M, Griebel M, Sharp G, Gibson J (2011) Pitfalls in measuring cerebrospinal fluid glycine levels in infants with encephalopathy. J Child Neurol 26:703–706. https://doi.org/10.1177/0883073810389041CrossRefPubMed

Applegarth DA, Toone JR (2004) Glycine encephalopathy (nonketotic hyperglycinaemia): review and update. J Inherit Metab Dis 27:417–422. https://doi.org/10.1023/b:boli.0000031222.38328.59CrossRefPubMed

Applegarth DA, Toone JR (2006) Glycine encephalopathy (nonketotic hyperglycinemia): comments and speculations. Am J Med Genet A 140:186–188. https://doi.org/10.1002/ajmg.a.31030CrossRefPubMed

Applegarth DA, Toone JR, Lowry RB (2000) Incidence of inborn errors of metabolism in British Columbia, 1969–1996. Pediatrics 105:e10. https://doi.org/10.1542/peds.105.1.e10CrossRefPubMed

Azize NA, Ngah WZ, Othman Z, Ngah WZ, Othman Z, Desa N, Chin BC et al (2014) Mutation analysis of glycine decarboxylase, aminomethyltransferase and glycine cleavage system protein-H genes in 13 unrelated families with glycine encephalopathy. J Hum Genet 59:593–597. https://doi.org/10.1038/jhg.2014.69CrossRefPubMed

Baker PR II, Friederich MW, Swanson MA, Shaikh T, Bhattacharya K, Scharer GH, Aicher J et al (2014) Variant non ketotic hyperglycinemia is caused by mutations in LIAS, BOLA3 and the novel gene GLRX5. Brain 137:366–379. https://doi.org/10.1093/brain/awt328CrossRefPubMed

Bravo-Alonso I, Navarrete R, Arribas-Carreira L, Perona A, Abia D, Couce ML, Garcia-Cazorla A et al (2017) Nonketotic hyperglycinemia: Functional assessment of missense variants in GLDC to understand phenotypes of the disease. Hum Mutat 38:678–691. https://doi.org/10.1002/humu.23208CrossRefPubMed

Chiu CF, Lin JL, Lin JJ, Tseng MH, Lo FS, Chiang MC (2016) Nonketotic Hyperglycinemia of Infants in Taiwan. Pediatr Neonatol 57:420–426. https://doi.org/10.1016/j.pedneo.2015.10.008CrossRefPubMed

Conter C, Rolland MO, Cheillan D, Bonnet V, Maire I, Froissart R (2006) Genetic heterogeneity of the GLDC gene in 28 unrelated patients with glycine encephalopathy. J Inherit Metab Dis 29:135–142. https://doi.org/10.1007/s10545-006-0202-6CrossRefPubMed

Coughlin CR II, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Väisänen ML et al (2017) The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT [published correction appears in Genet Med. 2018 Jan 04;:]. Genet Med 19:104-111. https://doi.org/10.1038/gim.2016.74

Cusmai R, Martinelli D, Moavero R, Carlo Dionisi Vici CD, Vigevano F, Castana C, Elia M, Bernabei S, Bevivino E (2012) Ketogenic diet in early myoclonic encephalopathy due to non ketotic hyperglycinemia. Eur J Paediatr Neurol 16:509–513. https://doi.org/10.1016/j.ejpn.2011.12.015CrossRefPubMed

Dinopoulos A, Matsubara Y, Kure S (2005) Atypical variants of nonketotic hyperglycinemia. Mol Genet Metab 86:61–69. https://doi.org/10.1016/j.ymgme.2005.07.016CrossRefPubMed

Genç Sel Ç, Kılıç M, Yüksel D, Aksoy A, Kasapkara CS, Ceylaner S, Karli-Oguz K (2018) Nonketotic hyperglycinemia: Clinical range and outcome of a rare neurometabolic disease in a single-center. Brain Dev 40:865–875. https://doi.org/10.1016/j.braindev.2018.06.007CrossRefPubMed

Hennermann JB, Berger JM, Grieben U, Scharer G, Van Hove JL (2012) Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis 35:253–261. https://doi.org/10.1007/s10545-011-9398-1CrossRefPubMed

Hoover-Fong JE, Shah S, Van Hove JL, Applegarth D, Toone J, Hamosh A (2004) Natural history of nonketotic hyperglycinemia in 65 patients. Neurology 63:1847–1853. https://doi.org/10.1212/01.wnl.0000144270.83080.29CrossRefPubMed

Kanno J, Hutchin T, Kamada F, Narisawa A, Aoki Y, Matsubara Y, Kure S (2007) Genomic deletion within GLDC is a major cause of non-ketotic hyperglycinaemia. J Med Genet 44:e69. https://doi.org/10.1136/jmg.2006.043448CrossRefPubMedPubMedCentral

Kava MP, Robertson A, Greed L, Balasubramaniam S (2019) Ketogenic diet, a potentially valuable therapeutic option for the management of refractory epilepsy in classical neonatal nonketotic hyperglycinemia: a case report. Eur J Clin Nutr 73:961–965. https://doi.org/10.1038/s41430-018-0286-8CrossRefPubMed

Korman SH, Gutman A (2002) Pitfalls in the diagnosis of glycine encephalopathy (non-ketotic hyperglycinemia). Dev Med Child Neurol 44:712–720. https://doi.org/10.1017/s0012162201002808CrossRefPubMed

Kure S, Takayanagi M, Narisawa K, Tada K, Leisti J (1992) Identification of a common mutation in Finnish patients with nonketotic hyperglycinemia. J Clin Invest 90:160–164. https://doi.org/10.1172/JCI115831CrossRefPubMedPubMedCentral

Kure S, Rolland MO, Leisti J, Mandel H, Sakata Y, Tada K, Matsubara Y, et al (1999) Prenatal diagnosis of non-ketotic hyperglycinaemia: enzymatic diagnosis in 28 families and DNA diagnosis detecting prevalent Finnish and Israeli-Arab mutations. Prenat Diagn 19:717–720. doi: https://doi.org/10.1002/(sici)1097-0223(199908)19:8<717::aid-pd625>3.0.co;2-l.CrossRefPubMed

Kure S, Kato K, Dinopoulos A, Gail C, deGrauw TJ, Christodoulou J, Bzduch V et al (2006) Comprehensive mutation analysis of GLDC, AMT, and GCSH in nonketotic hyperglycinemia. Hum Mutat 27:343–352. https://doi.org/10.1002/humu.20293CrossRefPubMed

Matalon R, Naidu S, Hughes JR, Michals K (1983) Nonketotic hyperglycinemia: treatment with diazepam–a competitor for glycine receptors. Pediatrics 71:581–584PubMed

Mohammad SA, Abdelkhalek HS (2017) Nonketotic hyperglycinemia: spectrum of imaging findings with emphasis on diffusion-weighted imaging. Neuroradiology 59:1155–1163. https://doi.org/10.1007/s00234-017-1913-0CrossRefPubMed

Nanao K, Okamura-Ikeda K, Motokawa Y, Danks DM, Baumgartner ER, Takada G, Hayasaka K (1994) Identification of the mutations in the T-protein gene causing typical and atypical nonketotic hyperglycinemia. Hum Genet 93:655–658. https://doi.org/10.1007/BF00201565CrossRefPubMed

Nasrallah F, Hadj-Taieb S, Chehida AB, Jelassi A, Massoued SB, Charfi M, Zidi W et al (2020) Nonketotic Hyperglycinemia in Tunisia. Report upon a Series of 69 Patients. Neuropediatrics. https://doi.org/10.1055/s-0040-1712489CrossRefPubMed

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW et al (2015) ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–424. https://doi.org/10.1038/gim.2015.30CrossRefPubMedPubMedCentral

Roy D, Al-Asmari A, Ghazal YK, Al-Oqiel S (2004) Nonketotic hyperglycinemia in Suleimaniah Children’s Hospital, Riyadh, Saudi Arabia. Ann Saudi Med 24:378–381. https://doi.org/10.5144/0256-4947.2004.378CrossRefPubMedPubMedCentral

Shbarou RM, Boustany RM, Daher RT, Pakdel P, Noureddine A, Karam PE (2019) Outcome of nonketotic hyperglycinemia in Lebanon: 14-year retrospective review. Neuropediatrics 50:235–243. https://doi.org/10.1055/s-0039-1692207CrossRefPubMed

Shin JH, Ahn SY, Shin JH, Sung SI, Jung JM, Kim JK, Kim ES et al (2012) Sequential magnetic resonance spectroscopic changes in a patient with nonketotic hyperglycinemia. Korean J Pediatr 55:301–305. https://doi.org/10.3345/kjp.2012.55.8.301CrossRefPubMedPubMedCentral

Stence NV, Fenton LZ, Levek C, Tong S, Coughlin CR II, Hennermann JB, Wortmann SB et al (2019) Brain imaging in classic nonketotic hyperglycinemia: Quantitative analysis and relation to phenotype. J Inherit Metab Dis 42:438–450. https://doi.org/10.1002/jimd.12072CrossRefPubMed

Swanson MA, Coughlin CR Jr, Scharer GH, Szerlong HJ, Bjoraker KJ, Spector EB, Creadon-Swindell G et al (2015) Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia [published correction appears in Ann Neurol 2016;79:505]. Ann Neurol 78:606–618. https://doi.org/10.1002/ana.24485CrossRefPubMedPubMedCentral

Tada K, Narisawa K, Yoshida T, Yokoyama K, Nakagawa H, Tanno K, Mochizukİ K et al (1969) Hyperglycinemia: a defect in glycine cleavage reaction. Tohuku J Exp Med 98:289–296CrossRef

Toone JR, Applegarth DA, Coulter-Mackie MB, James ER (2000) Biochemical and molecular investigations of patients with nonketotic hyperglycinemia. Mol Genet Metab 70:116–121. https://doi.org/10.1006/mgme.2000.3000CrossRefPubMed

Van Hove JL, Kishnani P, Muenzer J, Wenstrup RJ, Summar ML, Brummond MR, Lachiewicz AM et al (1995) Benzoate therapy and carnitine deficiency in non-ketotic hyperglycinemia. Am J Med Genet 59:444–453. https://doi.org/10.1002/ajmg.1320590410CrossRefPubMed

Van Hove JL, Kishnani PS, Demaerel P, Kahler SG, Miller C, Jaeken J, Rutledge SL (2000) Acute hydrocephalus in nonketotic hyperglycinemia. Neurology 54:754–756. https://doi.org/10.1212/wnl.54.3.754CrossRefPubMed

Van Hove JLK, Coughlin C II, Swanson M, Hennermann JB (2002) [updated 2019] Nonketotic Hyperglycinemia In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. University of Washington, Seattle, 1993–2020

Van Hove JL, Vande Kerckhove K, Hennermann JB, Mahieu V, Declercq P, Mertens S, De Becker M et al (2005) Benzoate treatment and the glycine index in nonketotic hyperglycinaemia. J Inherit Metab Dis 28:651–663. https://doi.org/10.1007/s10545-005-0033-xCrossRefPubMed

Van Hove JLK, Hennermann JB, Coughlin IICR (2016) Nonketotic Hyperglycinemia (Glycine Encephalopathy) and Lipoate Deficiency Disorders. In: Saudubray JM, Baumgartner MR, Walter J (eds) Inborn Metabolic Diseases, Diagnosis and Treatment, 6th edn. Springer, Berlin, pp 349–357CrossRef

Veríssimo C, Garcia P, Simões M, Robalo C, Henriques R, Diogo L, Grazina M (2013) Nonketotic hyperglycinemia: a cause of encephalopathy in children. J Child Neurol 28:251–254. https://doi.org/10.1177/0883073812441063CrossRefPubMed

von Wendt L, Hirvasniemi A, Similä S. Nonketotic hyperglycinemia (1979) A genetic study of 13 Finnish families. Clin Genet 15:411–417. https://doi.org/10.1111/j.1399-0004.1979.tb01773.xCrossRef

Wiltshire EJ, Poplawski NK, Harrison JR, Fletcher JM (2000) Treatment of late-onset nonketotic hyperglycinaemia: effectiveness of imipramine and benzoate. J Inherit Metab Dis 23:15–21. https://doi.org/10.1023/a:1005690611675CrossRefPubMed

Wolff JA, Kulovich S, Yu AL, Qiao CN, Nyhan WL (1986) The effectiveness of benzoate in the management of seizures in nonketotic hyperglycinemia. Am J Dis Child 140:596–602. https://doi.org/10.1001/archpedi.1986.02140200106038CrossRefPubMed

Titel: Genotypic and phenotypic features in Turkish patients with classic nonketotic hyperglycinemia
verfasst von: Harun Bayrak
Yılmaz Yıldız
Asburçe Olgaç
Çiğdem Seher Kasapkara
Aynur Küçükcongar
Ayşegül Zenciroğlu
Deniz Yüksel
Serdar Ceylaner
Mustafa Kılıç
Publikationsdatum: 01.04.2021
Verlag: Springer US
Erschienen in: Metabolic Brain Disease / Ausgabe 6/2021
Print ISSN: 0885-7490
Elektronische ISSN: 1573-7365
DOI: https://doi.org/10.1007/s11011-021-00718-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Circular RNA circ-ARFIP2 regulates proliferation, migration and invasion in human vascular smooth muscle cells via miR-338-3p-dependent modulation of KDR

Antiparkinsonian activity of Cucurbita pepo seeds along with possible underlying mechanism

Patients with cerebrotendinous xanthomatosis diagnosed with diverse multisystem involvement

Sexual dimorphism in rats exposed to maternal high fat diet: alterations in medullary sympathetic network

MiRNA-34c-5p protects against cerebral ischemia/reperfusion injury: involvement of anti-apoptotic and anti-inflammatory activities

LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis